The estimated Net Worth of Vii, L.P.Health Cap Vii Gp ... is at least $12.3 Milion dollars as of 30 June 2020. Vii Gp owns over 240,000 units of Aprea Therapeutics stock worth over $12,259,335 and over the last 5 years Vii sold APRE stock worth over $0.
Vii has made over 2 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Vii bought 240,000 units of APRE stock worth $4,080,000 on 30 June 2020.
The largest trade Vii's ever made was buying 266,667 units of Aprea Therapeutics stock on 7 October 2019 worth over $4,000,005. On average, Vii trades about 253,334 units every 134 days since 2019. As of 30 June 2020 Vii still owns at least 3,807,247 units of Aprea Therapeutics stock.
You can see the complete history of Vii Gp stock trades at the bottom of the page.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... oraz John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: